Quest Diagnosticsの株価は、収益が予想を上回ったため急騰し、投資会社の関心を高めています。 Quest Diagnostics' stock surges as earnings beat forecasts, boosting investment firm interests.

医療検査を主導するクエスト・ダイアグノスティクスは,2025年第1四半期に株式価値が上昇し,いくつかの投資会社が株式を増やした. Quest Diagnostics, a leading medical testing company, saw a boost in its stock value during the first quarter of 2025, with several investment firms increasing their stakes. 会社は1株あたり2.21ドルの強大な収益をアナリストの予想を超えて報告した. The company reported strong earnings of $2.21 per share, exceeding analysts' forecasts. クエスト・ダイアグノスティクスの株価は177.73ドルで,目標価格は185.73ドルで,平均的な"適度な買い"の評価があります. Quest Diagnostics' stock, trading at around $177.73, has a target price of $185.73 and an average "Moderate Buy" rating. 内部情報販売にもかかわらず,アナリストは,年間,株当たり9.70ドルの利益で,継続的な成長を予測しています. Despite some insider sales, analysts predict continued growth with $9.70 earnings per share for the year.